SkinBioTherapeutics plc (AIM:SBTX)

Market Cap	37.52M
Revenue (ttm)	2.68M
Net Income (ttm)	-2.58M
Shares Out	258.78M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	249,815
Average Volume	736,940
Open	14.85
Previous Close	14.50
Day's Range	14.33 - 14.85
52-Week Range	10.66 - 27.50
Beta	0.67
RSI	34.38
Earnings Date	Dec 2, 2025

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 15
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SBTX

Financial Performance

In 2024, SkinBioTherapeutics's revenue was 1.21 million, an increase of 815.26% compared to the previous year's 132,057. Losses were -2.88 million, 1.44% more than in 2023.